Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 4/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 5/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441697 | 0.86 | BRD4 (0.44) | SRD5A1BACE1BRD4SMYD2 | |
| SCHEMBL31441735 | 0.86 | BRD4 (0.44) | SRD5A1BACE1BRD4SMYD2 | |
| SCHEMBL31624781 | 0.84 | SMYD2 (0.36) | SRD5A1BACE1SMYD2 | |
| SCHEMBL20555296 | 0.84 | NPC1 (0.37) | SRD5A1BACE1SMYD2NPC1RAB9A | |
| SCHEMBL16401254 | 0.84 | BACE1 (0.36) | SRD5A1BACE1SMYD2NPC1RAB9A | |
| SCHEMBL1444038 | 0.80 | BACE1 (0.43) | BACE1SMYD2 | |
| SCHEMBL38652156 | 0.80 | RORC (0.41) | BACE1 | |
| SCHEMBL16409338 | 0.80 | RORC (0.41) | BACE1 | |
| SCHEMBL31441620 | 0.78 | BRD4 (0.35) | BACE1BRD4SMYD2 | |
| SCHEMBL21827847 | 0.78 | BACE1 (0.40) | BACE1SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | SRD5A1 3892/4885SRD5A2 4248/4885BACE1 17/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | SRD5A1 3904/4885SRD5A2 4262/4885BACE1 16/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | SRD5A1 3892/4885SRD5A2 4248/4885BACE1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.